The operative management of SBW has strong background both in CRO business as well as on drug discovery from the academic side. During a decede, SBW group has been working with over 100 companies in drug discovery projects, in addition our team has been in collaboration with many top academic groups in Europe on various scientific projects. We are also participating in many publicly funded R&D programs, including those funded by European Union, where we provide both our expertise as well as participate to develop novel methods for drug discovery and related life-science areas.
Petri Reponen, CEO of Novamass Ltd
Petri Reponen holds a M.Sc. in organic chemistry from University of Oulu. His PhD thesis titled “Identification and quantification of pesticide metabolites by LC-MS methods” is on preparation. Petri has special expertise in in vivo/ in vitro metabolism, ADME analytics and mass spectrometry.
Petri has a strong background in academic research. He has worked as a researcher and/ or lecturer at the University of Oulu in the departments of Pharmacology and Toxicology, Biomedicine, Chemistry, Medical Biochemistry and Molecular biology as well as Biochemistry. Petri has numerous publications in high-impact journals and he has presented his academic projects in several international scientific conferences. Petri is a member of the Association of Finnish Chemical Societies, Finnish Mass Spectrometry Society (FMSS) and Finnish Chromatographic Society.
Professor Mart Saarma
Academy Professor Mart Saarma is the Director of Center of Excellence of Molecular and Integrative Neuroscience.
Professor Saarma received his Ph.D. in molecular biology in 1975. He was the Head of the Department of Molecular Genetics, Estonian Academy of Sciences in 1980. From 1990 to 2010, he was the Director of the Institute of Biotechnology at the University of Helsinki.
Prof. Saarma is also chairman of the Board of Directors of the Finnish Genome Centre, member of the Estonian PMs Council for Science and Technology, chairman of the Scientific Advisory Board of the Heidelberg Neuroscience Center, Academician, Estonian Academy of Sciences (1990), Foreign Member of the Finnish Academy of Science (2000), Member of the European Molecular Biology Organization (EMBO) 2005 and member of several other boards.
Prof. Saarma is the author of more than 150 scientific papers and 15 patents. His research areas are in the neurodegenerative disease (Parkinson’s and Alzheimer’s disease), especially GDNF family ligands GDNF and neurturin and their receptors, GFRa1-2 and RET. Prof. Saarma is also board member and member of scientific advisory boards of many biotechnology companies.
>>Find our more on professor Saarma’s research on this page
Professor Arto Urtti
Professor Arto Urtti is the Directory of Centre for Drug Research (previously DDTC – Drug Discovery and Development Technology Center) and professor of Biopharmaceutics at University of Helsinki.
Professor Urtti received his Ph.D. degree in 1986. He served as Associate Professor of Pharmaceutical Technology and professor of Biopharmaceutics at University of Kuopio. Professor Urtti has obtained international research experience as a post-doctoral fellow (Dept. of Pharmaceutical Chemistry, University of Kansas) and visiting professor (Dept. of Bio-Pharmaceutical Sciences, University of California San Francisco and Department of Pharmaceutics, University of Wisconsin).
Professor Urtti’s research programme is presented in over 200 peer-reviewed articles and 20 patents and patent applications. Professor Urtti’s main research fields are drug delivery (controlled release, computational and cell-based methods for ADME research) and nanotechnology (biomaterial structures for drug and gene targeting and for 3-d cell culture. Professor Urtti has been granted many awards for his research, also including Millenium Distinction Award 2009.
>>Find our more on professor Urtti’s research on this page
Adjunct professor (Docent) Moshe Finel
Dr Finel is a Group leader at the Centre for Drug Research (CDR), Faculty of Pharmacy, University of Helsinki, Finland. Dr. Finel got his M.Sc. in Life Sciences in 1983 from the Weizmann Institute of Science, Rehovot, Israel and his Ph.D. in Biochemistry in 1989 from the University of Helsinki. He obtained postdoctoral training in the Laboratory of Molecular Biology, Medical Research Council, Cambridge, UK. Dr. Finel has published over 100 publications and he has supervised many Ph.D. theses. Dr. Finel’s current research interests are in Phase II drug metabolism, mainly the glucuronidation of drugs and related compounds, as well as the enzymes that catalyze these reactions, the UDP-glucuronosyltransferases (UGTs).
>>Find our more on Adjunct professor Finel’s research on this page